These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9337452)

  • 1. Ursodiol to prevent hepatic venoocclusive disease.
    Comcowich SA; Spitzer TR; Tsunoda SM
    Ann Pharmacother; 1997 Oct; 31(10):1249-52. PubMed ID: 9337452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients.
    Essell JH; Thompson JM; Harman GS; Halvorson RD; Snyder MJ; Callander NS; Clement DJ
    Bone Marrow Transplant; 1992 Oct; 10(4):367-72. PubMed ID: 1422493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation.
    Park SH; Lee MH; Lee H; Kim HS; Kim K; Kim WS; Jung CW; Im YH; Yoon SS; Kang WK; Park K; Park CH; Kim SW
    Bone Marrow Transplant; 2002 Jan; 29(2):137-43. PubMed ID: 11850708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome.
    Ozkaynak MF; Weinberg K; Kohn D; Sender L; Parkman R; Lenarsky C
    Bone Marrow Transplant; 1991 Jun; 7(6):467-74. PubMed ID: 1908340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
    Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How can we reduce hepatic veno-occlusive disease-related deaths after allogeneic stem cell transplantation?
    Johnson DB; Savani BN
    Exp Hematol; 2012 Jul; 40(7):513-7. PubMed ID: 22542577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A trial use of prostaglandin E1 for prevention of hepatic veno-occlusive disease after allogeneic bone marrow transplantation].
    Morio S; Oh H; Kogure K; Ishii H; Ishii A; Nakaseko C; Ikegami T; Kawano E; Matsuura Y; Nishimura M
    Rinsho Ketsueki; 1994 Sep; 35(9):846-52. PubMed ID: 7967053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of PGE1 to prevent veno-occlusive disease of the liver after bone marrow transplantation.
    Gluckman E; Jolivet I; Scrobohaci ML; Devergie A; Traineau R; Bourdeau-Espérou H; Lehn P; Faure P; Drouet L
    Nouv Rev Fr Hematol (1978); 1990; 32(1):1-3. PubMed ID: 2349075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia.
    Rozman C; Carreras E; Qian C; Gale RP; Bortin MM; Rowlings PA; Ash RC; Champlin RE; Henslee-Downey PJ; Herzig RH; Hinterberger W; Klein JP; Prentice HG; Reiffers J; Zwaan FE; Horowitz MM
    Bone Marrow Transplant; 1996 Jan; 17(1):75-80. PubMed ID: 8673059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors.
    Hasegawa S; Horibe K; Kawabe T; Kato K; Kojima S; Matsuyama T; Hirabayashi N
    Bone Marrow Transplant; 1998 Dec; 22(12):1191-7. PubMed ID: 9894723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Veno-occlusive disease of the liver].
    Rybicka M; Krysiak R; Okopień B
    Wiad Lek; 2009; 62(1):42-51. PubMed ID: 19817257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Veno-occlusive disease of the liver complicating bone marrow transplantation.
    Baglin TP
    Bone Marrow Transplant; 1994 Jan; 13(1):1-4. PubMed ID: 8019444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.
    Styler MJ; Crilley P; Biggs J; Moul J; Copelan E; Topolsky D; Avalos B; Penza S; Sabol P; Downs K; Szer J; Brodsky I; Marks DI
    Bone Marrow Transplant; 1996 Jul; 18(1):171-6. PubMed ID: 8832011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.
    Lee JH; Choi SJ; Lee JH; Kim SE; Park CJ; Chi HS; Lee MS; Lee JS; Kim WK; Lee KH
    Ann Hematol; 2005 May; 84(5):321-30. PubMed ID: 15580502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin.
    Simon M; Hahn T; Ford LA; Anderson B; Swinnich D; Baer MR; Bambach B; Bernstein SH; Bernstein ZP; Czuczman MS; Slack JL; Wetzler M; Herzig G; Schriber J; McCarthy PL
    Bone Marrow Transplant; 2001 Mar; 27(6):627-33. PubMed ID: 11319593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment.
    Lee JH; Lee KH; Choi JS; Zang DY; Kim SB; Kim SW; Suh C; Lee JS; Kim WK; Lee YS; Kim SH
    J Korean Med Sci; 1996 Apr; 11(2):118-26. PubMed ID: 8835758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low incidence of hepatic veno-occlusive disease in pediatric patients undergoing hematopoietic stem cell transplantation attributed to a combination of intravenous heparin, oral glutamine, and ursodiol at a single transplant institution.
    Lakshminarayanan S; Sahdev I; Goyal M; Vlachos A; Atlas M; Lipton JM
    Pediatr Transplant; 2010 Aug; 14(5):618-21. PubMed ID: 20051023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial.
    Essell JH; Schroeder MT; Harman GS; Halvorson R; Lew V; Callander N; Snyder M; Lewis SK; Allerton JP; Thompson JM
    Ann Intern Med; 1998 Jun; 128(12 Pt 1):975-81. PubMed ID: 9625683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation.
    Toh HC; McAfee SL; Sackstein R; Cox BF; Colby C; Spitzer TR
    Bone Marrow Transplant; 1999 Oct; 24(8):891-5. PubMed ID: 10516702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
    Brice K; Valerie B; Claire G; Valerie M; Yves B; Gilles A; Nathalie B
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):135-43. PubMed ID: 17952879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.